Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arnovie101 in B Cell-Mediated Autoimmune Diseases
NCT07629596Phase 1Recruiting
- Sponsor
- Circunited
- Start
- Apr 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Arnovie101 in systemic lupus erythematosus (SLE) and autoimmune hemolytic anemia (AIHA), sponsored by Circunited. Primary endpoints: Dose-Limiting Toxicity at 12 months and Adverse Events and Serious Adverse Events at 12 months. Started Apr 2026; status: recruiting.
02
Drugs
Arnovie101
03
Conditions
systemic lupus erythematosus (SLE)autoimmune hemolytic anemia (AIHA)
Beyond the preview
Go deeper on NCT07629596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07629596.